-
公开(公告)号:US06455510B1
公开(公告)日:2002-09-24
申请号:US09530573
申请日:2000-06-15
IPC分类号: A61K3170
CPC分类号: C07H19/16
摘要: A compound of formula (I) which is an agonist at the adenosine A1 receptor wherein R2 represents C1-3alkyl, halogen or hydrogen; R3 represents a fluorinated straight or branched alkyl group of 1-6 carbon atoms and salts and solvates thereof, in particular, physiologically acceptable solvates and salts thereof. These compounds are agonists at the adenosine A1 receptor.
摘要翻译: 式(I)化合物,其为腺苷A1受体的激动剂,其中R2表示C1-3烷基,卤素或氢; R3表示1-6个碳原子的氟化直链或支链烷基及其盐和溶剂化物,特别是其生理上可接受的溶剂合物及其盐。 这些化合物是腺苷A1受体的激动剂。
-
公开(公告)号:US06492348B1
公开(公告)日:2002-12-10
申请号:US09736018
申请日:2001-03-06
申请人: David Edmund Bays , Richard Peter Charles Cousins , Hazel Joan Dyke , Colin David Eldred , Brian David Judkins , Martin Pass , Andrew Michael Kenneth Pennell
发明人: David Edmund Bays , Richard Peter Charles Cousins , Hazel Joan Dyke , Colin David Eldred , Brian David Judkins , Martin Pass , Andrew Michael Kenneth Pennell
IPC分类号: A61K3170
CPC分类号: C07D473/00 , C07H19/16
摘要: A compound of formula (I) which is an agonist at the adenosine Al receptor, wherein Y, Z, and W represent heteroatoms, and salts and solvates thereof, in particular, physiologically acceptable solvates and salts thereof for use in therapy.
摘要翻译: 作为腺苷A1受体的激动剂的式(I)化合物,其中Y,Z和W表示杂原子,以及其盐和溶剂化物,特别是用于治疗的生理学上可接受的溶剂合物及其盐。
-
公开(公告)号:US06677316B2
公开(公告)日:2004-01-13
申请号:US10217107
申请日:2002-08-13
申请人: David Edmund Bays , Richard Peter Charles Cousins , Hazel Joan Dyke , Colin David Eldred , Brian David Judkins , Martin Pass , Andrew Michael Kenneth Pennell
发明人: David Edmund Bays , Richard Peter Charles Cousins , Hazel Joan Dyke , Colin David Eldred , Brian David Judkins , Martin Pass , Andrew Michael Kenneth Pennell
IPC分类号: A61K3170
CPC分类号: C07D473/00 , C07H19/16
摘要: A method of treating a patient suffering from or susceptible to ischemic heart disease, peripheral vascular disease or stroke or which subject is suffering pain, a CNS disorder or sleep apnea which comprises administering a therapeutically effective amount of an adenosine derivative which is an agonist at the adenosine A1 receptor and which exhibits little or no agonist activity of the A3 receptor. The adenosine derivative has a general formula (I) as follows:
摘要翻译: 治疗患有或易患缺血性心脏病,外周血管疾病或中风或受试者患有疼痛,CNS病症或睡眠呼吸暂停症的患者的方法,其包括给予治疗有效量的作为激动剂的腺苷衍生物 腺苷A1受体并且其表现出很少或没有A3受体的激动剂活性。 腺苷衍生物具有如下通式(I):
-
公开(公告)号:US5998388A
公开(公告)日:1999-12-07
申请号:US180442
申请日:1998-11-06
申请人: Frank Ellis , Stephen Swanson , Richard Peter Charles , Brian Cox , Andrew Michael Kenneth Pennell , Colin David Eldred
发明人: Frank Ellis , Stephen Swanson , Richard Peter Charles , Brian Cox , Andrew Michael Kenneth Pennell , Colin David Eldred
IPC分类号: C07H19/167 , A61K31/7076 , A61P9/00 , A61P25/00 , C07H15/04 , C07H19/16 , A61K31/70
摘要: This invention relates to novel adenosine derivatives, to processes for their preparation, to pharmaceutical compositions containing them and to their use in medicine. Thus the invention provides compounds of formula (I) which are agonists at the adenosine A1 receptor. ##STR1## wherein R.sup.1 represents phenyl optionally substituted by one or more substituents selected from halogen, C.sub.1-3 alkyl, trifluoromethyl, nitro, cyano, --CO.sub.2 R.sup.a.sub.1 --CONR.sup.a R.sup.b, --COR.sup.a, --SOR.sup.c, --SO.sub.2 R.sup.c, --SO.sub.3 H, --SO.sub.2 NR.sup.a R.sup.b, --OR.sup.a, --NHSO.sub.2 R.sup.c, --NHCOR.sup.a and --NR.sup.a R.sup.b,R.sup.2 represents a C.sub.1-6 alkyl or C.sub.3-6 alkenyl group; R.sup.3 represents C.sub.1-3 alkyl;R.sup.a and R.sup.b may each independently represent hydrogen or C.sub.1-3 alkyl or, when --NR.sup.a R.sup.b is directly attached to said phenyl, R.sup.a and R.sup.b together with the nitrogen atom may form a -5 or -6 or membered heterocyclic ring optionally containing a second heteroatom selected from oxygen or nitrogen, which second nitrogen heteroatom may optionally be further substituted by hydrogen or C.sub.1-3 alkyl;R.sup.c represents C.sub.1-3 alkyl;and salts and solvates thereof, in particular physiologically acceptable salts and solvates thereof.
摘要翻译: PCT No.PCT / EP97 / 02403 Sec。 371日期:1998年11月6日 102(e)日期1998年11月6日PCT提交1997年5月13日PCT公布。 WO97 / 43300 PCT出版物 日期1997年11月20日本发明涉及新型腺苷衍生物,其制备方法,含有它们的药物组合物及其在医药中的用途。 因此,本发明提供了作为腺苷A1受体的激动剂的式(I)化合物。 其中R 1表示任选被一个或多个选自卤素,C 1-3烷基,三氟甲基,硝基,氰基,-CO 2 R 1a -CONR a R b,-COR a,-SOR c,-SO 2 Rc,-SO 3 H,-SO 2 NR a R b,-OR a,-NHSO 2 R c ,-NHCOR a和-NR a R b,R 2表示C 1-6烷基或C 3-6烯基; R 3表示C 1-3烷基; R a和R b可各自独立地表示氢或C 1-3烷基,或当-NR a R b直接与所述苯基连接时,R a和R b与氮原子一起可以形成任选地含有选自第二杂原子的-5或-6元杂环 来自氧或氮,该第二氮杂原子可以任选地被氢或C 1-3烷基进一步取代; Rc表示C1-3烷基; 及其盐和溶剂合物,特别是其生理上可接受的盐和溶剂化物。
-
公开(公告)号:US06740644B2
公开(公告)日:2004-05-25
申请号:US10373064
申请日:2003-02-26
IPC分类号: A61K3170
摘要: A compound of formula (I), wherein R2 represents C1-3alkyl, halogen or hydrogen; R3 represents straight or branched alkyl group of 1-6 carbon atoms; with the proviso that, when R3 represents C1-3alkyl, R2 represents C1-3alkyl, R1 cannot represent phenyl optionally substituted by one or more substituents selected from halogen, C1-3alkyl, trifluoromethyl, nitro, cyano, —CO2Rc, —CONRcRd, —CORc, —SORe, —SO2Re, —SO3H, —SO2NRcRd, —ORc, —NHSO2Re, —NHCORc and —NRcRd; and salts and solvates thereof, in particular, physiologically acceptable solvates and salts thereof. These compounds are agonists at the Adenosine A1 receptor.
摘要翻译: 式(I)的化合物,其中R 2表示C 1-3烷基,卤素或氢; R 3表示1-6个碳原子的直链或支链烷基; 条件是当R 3表示C 1-3烷基时,R 2表示C 1-3烷基,R 1不能表示任选被一个或多个选自卤素,C 1-3烷基,三氟甲基,硝基, 氰基,-CO 2 R c,-CONR c R d,-COR c,-SOR e,-SO 2 R e,-SO 3 H,-SO 2 NR c R d, OR c,-NHSO 2 R e,-NHCOR c和-NR c R d; 特别是其生理上可接受的溶剂合物及其盐。 这些化合物是腺苷A1受体的激动剂。
-
公开(公告)号:US06544960B1
公开(公告)日:2003-04-08
申请号:US09530575
申请日:2000-06-15
IPC分类号: A61K3170
摘要: A compound of formula (I), wherein R2 represents C1-3alkyl, halogen or hydrogen; R3 represents straight or branched alkyl group of 1-6 carbon atoms; with the proviso that, when R3 represents C1-3alkyl, R2 represents C1-3alkyl, R1 cannot represent phenyl optionally substituted by one or more substituents selected from halogen, C1-3alkyl, trifluoromethyl, nitro, cyano, —CO2Rc, —CONRcRd, —CORc, —SORe, SO2Re, —SO3H, —SO2NRcRd, —ORc, —NHSO2Re, —NHCORc and —NRcRd; and salts and solvates thereof, in particular, physiologically acceptable solvates and salts thereof. These compounds are agonists at the Adenosine Al receptor.
摘要翻译: 式(I)的化合物,其中R 2表示C 1-3烷基,卤素或氢; R3表示1-6个碳原子的直链或支链烷基; 条件是当R 3表示C 1-3烷基时,R 2表示C 1-3烷基,R 1不能表示任选被一个或多个选自卤素,C 1-3烷基,三氟甲基,硝基,氰基,-CO 2 R c,-CONRc R d, CORc,-SORe,SO2Re,-SO3H,-SO2NRcRd,-ORc,-NHSO2Re,-NHCORc和-NRcRd; 特别是其生理上可接受的溶剂合物及其盐。 这些化合物是腺苷A1受体的激动剂。
-
公开(公告)号:US06407076B1
公开(公告)日:2002-06-18
申请号:US09530574
申请日:2000-06-27
IPC分类号: A61K3170
CPC分类号: C07H19/16
摘要: A compound of formula (I) wherein R2 represents C1-3 alkyl, halogen or hydrogen; R3 represents a fluorinated straight or branched alkyl group of 1-6 carbon atoms; and salts and solvates thereof, in particular, physiologically acceptable solvates and salts thereof. These compounds are agonists of the Adenosine A1 receptor.
摘要翻译: 式(I)的化合物,其中R 2表示C 1-3烷基,卤素或氢; R3表示1-6个碳原子的氟化直链或支链烷基; 特别是其生理上可接受的溶剂合物及其盐。 这些化合物是腺苷A1受体的激动剂。
-
公开(公告)号:US6020346A
公开(公告)日:2000-02-01
申请号:US849727
申请日:1997-07-08
申请人: Duncan Robert Armour , Gerard Martin Paul Giblin , Andrew Michael Kenneth Pennell , Peter John Sharratt
发明人: Duncan Robert Armour , Gerard Martin Paul Giblin , Andrew Michael Kenneth Pennell , Peter John Sharratt
IPC分类号: A61K31/4427 , A61K31/445 , A61P1/00 , A61P1/08 , A61P25/00 , A61P25/04 , A61P29/00 , A61P37/00 , A61P37/08 , A61P43/00 , C07D401/12
CPC分类号: C07D401/12
摘要: The present invention relates to piperidine derivatives of formula (I): ##STR1## wherein the substituents R.sup.1, R.sup.3, R.sup.4 and R.sup.5 are as defined in the specification and claims, and the substituent R.sup.2 is ##STR2## The pharmaceutically acceptable salts and solvates of these piperidine derivatives are also described. The invention also relates to processes for the preparation of the piperidine derivatives, and to their use in the treatment of conditions mediated by tachykinins.
摘要翻译: PCT No.PCT / EP96 / 00082 Sec。 371日期1997年7月8日 102(e)日期1997年7月8日PCT 1996年1月10日PCT PCT。 WO96 / 21661 PCT出版物 日期:1996年7月18日本发明涉及式(I)的哌啶衍生物:其中取代基R 1,R 3,R 4和R 5如说明书和权利要求中所定义,取代基R 2为这些的药学上可接受的盐和溶剂合物 哌啶衍生物也被描述。 本发明还涉及制备哌啶衍生物的方法及其用于治疗由速激肽介导的病症的用途。
-
-
-
-
-
-
-